Innovation New Jersey
  • Home
  • Our Coalition
    • Contact Us
  • News
  • Resources
    • State Supports
    • Federal Supports
    • Higher Ed Supports
  • Join Us

Innovation News

Everything Innovation. Everything New Jersey.
Follow us and stay connected.

NOL Approvals Top $1 Billion as Program Celebrates its 20th Anniversary

12/8/2018

0 Comments

 
TRENTON (December 7, 2018) – The New Jersey Economic Development Authority (EDA) today announced that it has approved more than $1 billion in funding for over 540 technology and life sciences companies through the Technology Business Tax Certificate Transfer Program, more commonly known as the Net Operating Loss (NOL) Program, since the program’s inception 20 years ago.
Heralded as a lifeline for companies going through unprofitable times, the NOL Program enables eligible technology and life-sciences companies to sell New Jersey net operating losses and unused research and development tax credits to unrelated profitable corporations for cash. The cash can then be used for working capital or to fund research. The EDA and the New Jersey Department of Treasury’s Division of Taxation administer the program.

This year, 48 companies were approved to share $60 million through the NOL Program, the maximum amount of funding allocated for the program. Of those, 14 companies are new to the program, a 27 percent increase from last year. Sixteen companies previously leveraged additional EDA resources, such as New Jersey Founders & Funders, the Angel Investor Tax Credit Program, and the Edison Innovation Fund. The EDA saw an 18 percent increase in the number of applications this year as compared to 2017, and the highest number since 2014. This year, the average award was $1.25 million.  
​
“The vision Governor Phil Murphy has laid out for the innovation economy reiterates the need for tools like the NOL Program to fuel technology and life sciences companies’ growth from their earliest stages through commercialization and beyond,” EDA Chief Executive Officer (CEO) Tim Sullivan. “This year’s roster of participating companies is doing promising work, and it will be fascinating to watch as they further develop their contributions to the state’s vast body of innovation.”

Participating companies hail from across New Jersey’s technology and life sciences industry. However, there was a particularly strong showing this year from the state’s biotechnology and health technology sectors, including the following first-time participants:
Celsion Corporation is a biopharmaceutical company that develops cancer treatments, including targeted chemotherapies and immunotherapies. The company’s clinical stage products focus on combatting liver and ovarian cancer. Celsion, which started in Maryland in 2000, relocated to Lawrenceville in 2011. The company currently employs 25 people.

“Since bringing Celsion here to tap into New Jersey’s tremendous pharmaceutical talent, I have been impressed by the array of resources the State offers life sciences companies like ours,” Celsion Chairman and CEO Michael Tardugno said. “The non-dilutive funding we received through the NOL Program will allow us to continue to bring our groundbreaking products through clinical trials and eventually to the marketplace.”  

Newark-based WellSheet Inc. applies physician-driven design and machine learning to Electronic Medical Records (EMRs) to improve the physician experience and early intervention for at-risk patients. Founded in 2015, the company currently has offices in New Jersey and New York, serving some of the largest hospitals in these states. WellSheet graduated from Newark Venture Partners’ NVP Labs program, a 10-week accelerator program, last year.

“We’re a relatively young company that has reaped the benefits of locating in New Jersey, such as access to the NVP Labs accelerator and the NOL Program,” Wellsheet CEO Craig Limoli said. “Funding from the NOL Program will allow us to build out our system and help even more doctors as they treat their patients.”

Jersey City-based TrialScope provides proven solutions designed to optimize the efficiency of clinical trial disclosure activities, maximize trial data transparency, and foster more informed, engaged patients through open research sharing. TrialScope previously received support from Edison VII, an Edison Partners venture fund in which the EDA invested. 

“We’re proud to offer our products and services to large and small pharmaceutical companies throughout the world and to support them with all their clinical trial transparency and compliance needs,” TrialScope CEO Jeff Kozloff said. “We were attracted to the NOL Program because it will allow us to raise working capital without giving up equity in our company.”

About the New Jersey Economic Development Authority
The New Jersey Economic Development Authority (NJEDA) serves as the State’s principal agency for driving economic growth.  The NJEDA is committed to making New Jersey a national model for inclusive and sustainable economic development by focusing on key strategies to help build strong and dynamic communities, create good jobs for New Jersey residents, and provide pathways to a stronger and fairer economy.  Through partnerships with a diverse range of stakeholders, the NJEDA creates and implements initiatives to enhance the economic vitality and quality of life in the State and strengthen New Jersey’s long-term economic competitiveness.

 To learn about the multitude of resources available to help technology and life sciences companies thrive, visit http://www.njeda.com/tls and follow @NewJerseyEDA on Facebook, Twitter and LinkedIn.
0 Comments



Leave a Reply.

    Do not miss a single innovative moment and sign up for our newsletter!
    Weekly updates


    Categories

    All
    3D Printing
    Academia
    Acquisitions
    Aerospace
    Agriculture
    AIDS
    Algae
    Alumni
    Animals
    Architecture
    Astrophysics
    Autism
    Awards
    Big Data
    Bioethics
    Biofuel
    Biomedical
    BioNJ
    Bioterrorism
    Bit Coins
    Brain Health
    Business
    Camden
    Cancer
    CCollege
    Cellular
    Centenary
    Chemistry
    ChooseNJ
    Climate Change
    Clinical Trials
    Cloud Tech
    Collaboration
    Computing
    Congress
    Coriell
    Council On Innovation
    Crowdfunding
    Cybersecurity
    DARPA
    Defense
    Degree
    Dementia
    Dental Health
    DOC
    DOD
    DOE
    Drew
    Drones
    Drug Creation
    Einstein's Alley
    Electricity
    Energy
    Engineering
    Entrepreneurship
    Environmental
    FAA
    Fairleigh Dickinson
    FDA
    Federal Budget
    Federal Government
    Federal Labs
    Federal Program
    Finance
    Food Science
    Fort Monmouth
    Fuel Cells
    Funding
    Genome
    Geography
    Geology
    Global Competition
    Google
    Governor Christie
    Grant
    Hackensack
    HackensackUMC
    Healthcare
    Health Care
    HHS
    HINJ
    Hospitals
    Immigration
    Incubator
    Infrastructure
    International
    Internet
    Investor
    IoT
    IP
    IT
    Jobs
    Johnson & Johnson
    K-12
    Kean
    Kessler
    Legislation
    Logistics
    Manufacturing
    Medical Devices
    Med School
    Mental Health
    Mentor
    Microorganisms
    Molecular Biology
    Montclair
    NAS
    Neuroscience
    Newark
    New Jersey
    NIFA
    NIH
    NIST
    NJBDA
    NJBIA
    NJ Chemistry Council
    NJCU
    NJDOLWD
    NJEDA
    NJEDge
    NJHF
    NJII
    NJIT
    NJMEP
    NJPAC
    NJPRO
    NJTC
    Nonprofit
    NSF
    OpEd
    Open Data
    OSHE
    OSTP
    Parasite
    Patents
    Paterson
    Patients
    Perth Amboy
    Pharma
    POTUS
    PPPL
    Princeton
    Prosthetics
    Ranking
    Rare Disease
    R&D Council
    Report
    Resiliency
    Rider
    Robotics
    Rowan
    Rutgers
    SBA
    Seton Hall
    Siemens
    Smart Car
    Smart Cities
    Software
    Solar
    Space
    SSTI
    Startup
    State Government
    STEM
    Stevens
    Stockton
    Subatomic
    Supports
    Sustainability
    Taxes
    TCNJ
    Teachers
    Telecom
    Therapy
    Thermodynamics
    Transportation
    Undergraduate
    USEDA
    Verizon
    Video Game
    Virtual Reality
    Water
    WHO
    William Paterson
    Women In STEM
    Workforce Development

Powered by Create your own unique website with customizable templates.